# Phase 1 Lupus Erythematosus, Systemic trials: 90 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 90 trials in phase 1 for Lupus Erythematosus, Systemic that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Lupus Erythematosus, Systemic trials: 90 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/lupus-erythematosus-systemic

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 90
- Recruiting or not yet: 90
- Read on: November 19, 2026

## Trials

The 25 newest of 90, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 13, 2026 | NCT07934472 | A Study to Evaluate the Placental Transfer of Dapirolizumab Pegol to the Infant(s) From Pregnant Study Participants With Active Systemic... | UCB Biopharma SRL | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934472) |
| November 6, 2026 | NCT07923747 | An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE) | Novartis Pharmaceuticals | Phase 1 | Not yet recruiting | Rheumatoid Arthritis and Systemic Lupus Erythematosus | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923747) |
| October 30, 2026 | NCT07906145 | A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases | Shanghai Qilu Pharmaceutical Research and Development Center LTD | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Rheumatoid Arthritis (RA), Primary Sjögren's Syndrome (pSS), Systemic Sclerosis (SSc) | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906145) |
| October 14, 2026 | NCT07873931 | A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases | Bristol-Myers Squibb | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies, Systemic... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873931) |
| October 2, 2026 | NCT07855302 | CD19 CAR-T Therapy for Refractory Childhood-Onset Systemic Lupus Erythematosus | Seoul National University Hospital | Phase 1 | Recruiting | Childhood-Onset Systemic Lupus Erythematosus, Refractory SLE, CD19 CAR-T Cell Therapy | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855302) |
| September 21, 2026 | NCT07829614 | F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus Erythematosus | Shandong New Time Pharmaceutical Co., LTD | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE) | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829614) |
| August 7, 2026 | NCT07751315 | A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases | Qilu Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Primary Sjögren's Syndrome | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751315) |
| July 28, 2026 | NCT07732309 | A Study of ATG-201 in Adult Participants With Autoimmune Diseases | Antengene Biologics Limited | Phase 1 | Recruiting | Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Sjogren's Disease, Autoimmune Diseases | 149 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07732309) |
| July 7, 2026 | NCT07688980 | Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or... | AstraZeneca | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07688980) |
| June 30, 2026 | NCT07676266 | A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy | The Affiliated Hospital of Qingdao University | Phase 1 | Not yet recruiting | Multiple Sclerosis (MS), Myasthenia Gravis (MG), Neuromyelitis Optica Spectrum Disorder, Systemic Lupus Erythematosus... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07676266) |
| June 16, 2026 | NCT07649265 | A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Recruiting | Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Sjögren's Disease | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649265) |
| June 5, 2026 | NCT07629583 | To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis | Genentech, Inc. | Phase 1 | Recruiting | Lupus Erythematosus, Systemic | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07629583) |
| May 27, 2026 | NCT07607964 | A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous... | AbbVie | Phase 1 | Recruiting | Systemic Lupus Erythematosus, Rheumatoid Arthritis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07607964) |
| April 22, 2026 | NCT07544225 | Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic... | Gustave Roussy, Cancer Campus, Grand Paris | Phase 1 | Not yet recruiting | Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Sjogren's Disease With Dry Eyes, Systemic Sclerosis... | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07544225) |
| April 13, 2026 | NCT07523282 | Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases | Shenzhen MagicRNA Biotechnology Co., Ltd | Phase 1 | Not yet recruiting | Autoimmune Disease, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523282) |
| April 8, 2026 | NCT07516639 | First-in-Human Study of ISH0613: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics | SUNHO（China）BioPharmaceutical CO., Ltd. | Phase 1 | Not yet recruiting | Healthy Subjects (HS), SLE (Systemic Lupus) | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516639) |
| April 6, 2026 | NCT07512947 | Study of YKST02 Alone or in Combination With YK012 in Patients With Active or Refractory Systemic Lupus Erythematosus | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 | Not yet recruiting | System Lupus Erythematosus(SLE) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07512947) |
| March 24, 2026 | NCT07490275 | Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | Not yet recruiting | Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis, Refractory /... | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07490275) |
| March 19, 2026 | NCT07483346 | IASO-782 in Systemic Lupus Erythematosus | Shanghai IASO Biotechnology Co., Ltd | Phase 1 | Recruiting | SLE - Systemic Lupus Erythematosus | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07483346) |
| March 2, 2026 | NCT07444307 | A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus | Hangzhou Qihan Biotech Co., Ltd. | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444307) |
| February 27, 2026 | NCT07439029 | YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases | Children's Hospital of Fudan University | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus (SLE), Diffuse Systemic Sclerosis, Idiopathic Inflammatory Myopathies (IIMs), ANCA... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07439029) |
| February 25, 2026 | NCT07432334 | CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus | Vinmec Research Institute of Stem Cell and Gene Technology | Phase 1 | Recruiting | Refractory Systemic Lupus Erythematosus | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07432334) |
| February 17, 2026 | NCT07413341 | A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases | Therorna | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS), Systemic Sclerosis (SSc), Inflammatory Myopathy, ANCA... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07413341) |
| February 13, 2026 | NCT07408908 | Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants.. | Xiamen Amoytop Biotech Co., Ltd. | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07408908) |
| February 11, 2026 | NCT07403097 | Study of CD19 CAR-T Therapy for Refractory SLE | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Systemic Lupus Erythematosus | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07403097) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| China Immunotech (Beijing) Biotechnology Co., Ltd. | 5 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 5 |
| [Chongqing Precision Biotech Co., Ltd](https://specstream.ai/data/clinical-trials/company/chongqing-precision-biotech-co-ltd) | 4 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 3 |
| Institute of Hematology & Blood Diseases Hospital, China | 3 |
| The Children's Hospital of Zhejiang University School of Medicine | 3 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 2 |
| Beijing GoBroad Hospital | 2 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 2 |
| Shenzhen MagicRNA Biotechnology Co., Ltd | 2 |
| HC Biopharma Inc. | 2 |
| RenJi Hospital | 2 |
| Climb Bio, Inc. | 1 |
| National University of Malaysia | 1 |
| Antengene Biologics Limited | 1 |
| Candid Therapeutics | 1 |
| Capstan Therapeutics | 1 |
| Qilu Hospital of Shandong University | 1 |
| [Shandong New Time Pharmaceutical Co., LTD](https://specstream.ai/data/clinical-trials/company/shandong-new-time-pharmaceutical-co-ltd) | 1 |
| [Miltenyi Biomedicine GmbH](https://specstream.ai/data/clinical-trials/company/miltenyi-biomedicine-gmbh) | 1 |
| Changzhou No.2 People's Hospital | 1 |
| EdiGene Inc. | 1 |
| Luminary Therapeutics | 1 |
| CytoCares Inc | 1 |
| SUNHO（China）BioPharmaceutical CO., Ltd. | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 55 |
| United States | 20 |
| France | 10 |
| Spain | 9 |
| Australia | 9 |
| Germany | 7 |
| Japan | 5 |
| Georgia | 4 |
| Romania | 4 |
| Brazil | 4 |
| Netherlands | 3 |
| Canada | 3 |
| Belgium | 3 |
| Poland | 3 |
| Italy | 3 |
| United Kingdom | 3 |
| Taiwan | 3 |
| Bulgaria | 2 |
| Ukraine | 2 |
| Israel | 2 |
| Moldova | 2 |
| South Korea | 2 |
| Greece | 1 |
| Puerto Rico | 1 |
| Malaysia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [3D printing companies in the United States](https://specstream.ai/data/businesses/3d-printing-companies/united-states)
- [Artificial turf companies in the United States](https://specstream.ai/data/businesses/artificial-turf-companies/united-states)
- [B2B quarry companies in the United States](https://specstream.ai/data/businesses/b2b-quarry-companies/united-states)
- [Book magazine distribution companies in the United States](https://specstream.ai/data/businesses/book-magazine-distribution-companies/united-states)
- [Caterers in the United States](https://specstream.ai/data/businesses/caterers/united-states)
- [Concierge medicine practices in the United States](https://specstream.ai/data/businesses/concierge-medicine-practices/united-states)
